HIV/AIDS Support Organisation of Seychelles (HASO)

Email

hasoseychelles@yahoo.com

Phone

T: +248 4325108

Address

PSM Enterprises, C/O Dr Chetty’s Clinic, 2nd floor Lodge Street Victoria, Mahe Seychelles
About HIV/AIDS Support Organisation of Seychelles (HASO)

The HIV/AIDS Support Organisation (HASO) in Seychelles plays a key role in the national response to viral hepatitis, particularly hepatitis B and C, through advocacy, harm reduction, education, and community outreach. While HASO’s core mission centres on HIV, its work increasingly addresses the overlapping challenges of hepatitis, especially among people who inject drugs and other vulnerable populations.

Key Areas of Work:

  1. Awareness and Sensitisation
    HASO conducts awareness and sensitisation activities both among the general public and key populations, aiming to increase knowledge, reduce stigma, and encourage testing and treatment uptake for hepatitis.
  2. Community-Based Testing and Outreach
    The organisation delivers HIV and hepatitis C testing through door-to-door campaigns and targeted outreach at key hotspots. These efforts bring services directly to those most at risk and often underserved by traditional healthcare systems.
  3. Referral and Continuum of Care
    HASO facilitates referrals to appropriate health agencies for clients who require further treatment and medical care for hepatitis. This ensures that those who test positive are not lost in the system and are supported through the next steps of their health journey.
  4. Treatment Literacy and Adherence Support
    Through tailored treatment literacy sessions, HASO educates clients about hepatitis, its treatment options, and the importance of adherence. This empowers individuals to remain engaged in care and successfully complete their treatment.
  5. Advocacy and Rights-Based Support
    The organisation advocates on behalf of clients who are eligible for treatment, helping to navigate barriers such as access, eligibility criteria, or bureaucratic delays. HASO also campaigns for broader systemic changes to ensure inclusive, equitable access to hepatitis services.
  6. Harm Reduction and High-Risk Populations
    HASO co-founded the Drug Utilisation Response Network Seychelles (DURNS), a peer-led harm reduction initiative targeting people who inject drugs. This work includes education on safe injection practices and reducing hepatitis transmission within this high-risk group.
  7. Prison Outreach and Institutional Collaboration
    In partnership with the Seychelles Prison Service, HASO provides awareness and support services related to hepatitis and HIV among incarcerated populations, who face elevated risks due to limited access to care and increased exposure to risk factors.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close